Lily-developed anti-COVID drug entering Phase 3 of testing

(Photo Supplied/ Eli Lilly)

INDIANAPOLIS (WOWO): An Indiana-based drug firm has moved into the later stages of a potential COVID-19 antibody drug.

Eli Lily announced Monday it has moved into phase 3 of testing LY-COV555, which our Partners in News at ABC 21 say was developed in partnership with a Canadian biotech company, with up to 2,400 people who either work or live at nursing homes with a recent COVID-19 diagnosis.

The drug works by blocking the virus from attaching and entering into human cells.

The results should be known by the end of the year.


Please enter your comment!
Please enter your name here